Healthy subjects ( mean age 25.9 yrs ) and patients with COPD ( mean age 66 yrs , mean post-bronchodilator FEV1 60.1 % predicted normal value ) were randomised 2:1 to active treatment ( 400 , 1000 or 2800 g delivered doses of AZD9164 ) or placebo .